AB205535

Anti-ELOVL5 antibody [EPR17151]

RabMAb
Recombinant
What is this?

Be the first to review this product! Submit a review

(6 Publications)

Rabbit Recombinant Monoclonal ELOVL5 antibody. Suitable for WB, ICC/IF, Flow Cyt (Intra) and reacts with Mouse, Rat, Human samples. Cited in 6 publications.

View Alternative Names

ELOVL2, PRO0530, ELOVL5, Very long chain fatty acid elongase 5, 3-keto acyl-CoA synthase ELOVL5, ELOVL fatty acid elongase 5, Elongation of very long chain fatty acids protein 5, Fatty acid elongase 1, Very long chain 3-ketoacyl-CoA synthase 5, Very long chain 3-oxoacyl-CoA synthase 5, ELOVL FA elongase 5, hELO1

9 Images

Immunocytochemistry/ Immunofluorescence - Anti-ELOVL5 antibody [EPR17151] (AB205535)

ICC/IF

Supplier Data

Immunocytochemistry/ Immunofluorescence - Anti-ELOVL5 antibody [EPR17151] (AB205535)

Immunofluorescent analysis of 100% methanol-fixed, 0.1% Triton X-100 permeabilized HeLa (Human epithelial cells from cervix adenocarcinoma) cells labeling ELOVL5 with ab205535 at 1/100 dilution, followed by Goat anti-rabbit IgG (Alexa Fluor® 488) (ab150077) secondary antibody at 1/1000 dilution (green).

Confocal image showing cytoplasmic staining on HeLa cell line.

The nuclear counter stain is DAPI (blue).

Tubulin is detected with ab7291 (anti-Tubulin mouse mAb) at 1/1000 dilution and ab150120 (AlexaFluor®594 Goat anti-Mouse secondary) at 1/1000 dilution (red).

The negative controls are as follows : -

-ve control 1 : ab205535 at 1/100 dilution followed by ab150120 (AlexaFluor®594 Goat anti-Mouse secondary) at 1/1000 dilution.

-ve control 2 : ab7291 (anti-Tubulin mouse mAb) at 1/1000 dilution followed by ab150077 (Alexa Fluor®488 Goat Anti-Rabbit IgG H&L) at 1/1000 dilution.

ICC/IF

Supplier Data

Immunocytochemistry/ Immunofluorescence - Anti-ELOVL5 antibody [EPR17151] (AB205535)

Immunofluorescent analysis of 100% methanol-fixed, 0.1% Triton X-100 permeabilized HepG2 (Human liver hepatocellular carcinoma) cells labeling ELOVL5 with ab205535 at 1/100 dilution, followed by Goat anti-rabbit IgG (Alexa Fluor® 488) (ab150077) secondary antibody at 1/1000 dilution (green).

Confocal image showing cytoplasmic staining on HepG2 cell line.

The nuclear counter stain is DAPI (blue).

Tubulin is detected with ab7291 (anti-Tubulin mouse mAb) at 1/1000 dilution and ab150120 (AlexaFluor®594 Goat anti-Mouse secondary) at 1/1000 dilution (red).

The negative controls are as follows : -

-ve control 1 : ab205535 at 1/100 dilution followed by ab150120 (AlexaFluor®594 Goat anti-Mouse secondary) at 1/1000 dilution.

-ve control 2 : ab7291 (anti-Tubulin mouse mAb) at 1/1000 dilution followed by ab150077 (Alexa Fluor®488 Goat Anti-Rabbit IgG H&L) at 1/1000 dilution.

Flow Cytometry (Intracellular) - Anti-ELOVL5 antibody [EPR17151] (AB205535)

Flow Cyt (Intra)

Unknown

Flow Cytometry (Intracellular) - Anti-ELOVL5 antibody [EPR17151] (AB205535)

Intracellular Flow Cytometry analysis ofHeLa cells labelling ELOVL5 with ab205535 at 1/20 (red). Cells were fixed with 4% paraformaldehyde and permeabilized with 90% methanol. An Alexa Fluor^® 488-conjugated goat anti-rabbit IgG (1/2000) was used as the secondary antibody. Black - Isotype control, rabbit monoclonal IgG. Blue - Unlabelled control, cells without incubation with primary and secondary antibodies.

Supplier Data

Western blot - Anti-ELOVL5 antibody [EPR17151] (AB205535)

Blocking buffer and concentration : 5% NFDM/TBST. Diluting buffer and concentration : 5% NFDM/TBST. When testing sample with low protein level, we recommend uploading more amount of lysate, using lower antibody dilution, and using higher sensitivity ECL substrate. We also recommend trying 1%SDS Hot lysis prepare method to get desired Western Blot results.

All lanes:

Western blot - Anti-ELOVL5 antibody [EPR17151] (ab205535) at 1/1000 dilution

Lane 1:

HepG2 (Human hepatocellular carcinoma epithelial cell) whole cell lysate prepared in RIPA lysis method at 20 µg

Lane 2:

MCF7 (Human breast adenocarcinoma epithelial cell) whole cell lysate prepared in RIPA lysis method at 20 µg

Lane 3:

MCF7 (Human breast adenocarcinoma epithelial cell) whole cell lysate prepared in 1%SDS Hot lysis method at 20 µg

Lane 4:

HeLa (Human cervix adenocarcinoma epithelial cell) whole cell lysate prepared in RIPA lysis method at 20 µg

Lane 5:

HeLa (Human cervix adenocarcinoma epithelial cell) whole cell lysate prepared in 1%SDS Hot lysis method at 20 µg

Secondary

All lanes:

Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/20000 dilution

Predicted band size: 35 kDa

Observed band size: 35 kDa

false

Exposure time: 180s

Supplier Data

Western blot - Anti-ELOVL5 antibody [EPR17151] (AB205535)

Blocking/Dilution buffer : 5% NFDM/TBST.

All lanes:

Western blot - Anti-ELOVL5 antibody [EPR17151] (ab205535) at 1/1000 dilution

Lane 1:

Human fetal brain lysate at 10 µg

Lane 2:

Human fetal heart lysate at 10 µg

Lane 3:

Human fetal kidney lysate at 10 µg

Secondary

All lanes:

Anti-Rabbit IgG (HRP), specific to the non-reduced form of IgG at 1/10000 dilution

Predicted band size: 35 kDa

false

Exposure time: 30s

Supplier Data

Western blot - Anti-ELOVL5 antibody [EPR17151] (AB205535)

Blocking/Dilution buffer : 5% NFDM/TBST.

All lanes:

Western blot - Anti-ELOVL5 antibody [EPR17151] (ab205535) at 1/1000 dilution

All lanes:

Human testis lysate at 10 µg

Secondary

All lanes:

Anti-Rabbit IgG (HRP), specific to the non-reduced form of IgG at 1/10000 dilution

Predicted band size: 35 kDa

Observed band size: 35 kDa

false

Exposure time: 3min

Supplier Data

Western blot - Anti-ELOVL5 antibody [EPR17151] (AB205535)

Blocking/Dilution buffer : 5% NFDM/TBST.

All lanes:

Western blot - Anti-ELOVL5 antibody [EPR17151] (ab205535) at 1/1000 dilution

Lane 1:

C6 (Rat glial tumor cells) whole cell lysate at 10 µg

Lane 2:

RAW 264.7 (Mouse macrophage cells transformed with Abelson murine leukemia virus) whole cell lysate at 10 µg

Secondary

All lanes:

Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/10000 dilution

Predicted band size: 35 kDa

Observed band size: 35 kDa

false

Exposure time: 30s

Supplier Data

Western blot - Anti-ELOVL5 antibody [EPR17151] (AB205535)

Blocking/Dilution buffer : 5% NFDM/TBST.

All lanes:

Western blot - Anti-ELOVL5 antibody [EPR17151] (ab205535) at 1/1000 dilution

Lane 1:

Rat brain lysate at 10 µg

Lane 2:

Rat heart lysate at 10 µg

Lane 3:

Rat kidney lysate at 10 µg

Lane 4:

Rat spleen lysate at 10 µg

Secondary

All lanes:

Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/10000 dilution

Predicted band size: 35 kDa

Observed band size: 35 kDa

false

Exposure time: 15s

Supplier Data

Western blot - Anti-ELOVL5 antibody [EPR17151] (AB205535)

Blocking/Dilution buffer : 5% NFDM/TBST.

All lanes:

Western blot - Anti-ELOVL5 antibody [EPR17151] (ab205535) at 1/1000 dilution

Lane 1:

Mouse brain lysate at 10 µg

Lane 2:

Mouse heart lysate at 10 µg

Lane 3:

Mouse kidney lysate at 10 µg

Lane 4:

Mouse spleen lysate at 10 µg

Secondary

All lanes:

Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/10000 dilution

Predicted band size: 35 kDa

Observed band size: 35 kDa

false

Exposure time: 3min

Carrier free

Anti-ELOVL5 antibody [EPR17151] - BSA and Azide free

Key facts

Host species

Rabbit

Clonality

Monoclonal

Clone number

EPR17151

Isotype

IgG

Carrier free

Reacts with

Mouse, Rat, Human

Applications

ICC/IF, Flow Cyt (Intra), WB

applications

Immunogen

The exact immunogen used to generate this antibody is proprietary information.

Specificity

When testing sample with low protein level, we recommend uploading more amount of lysate, using lower antibody dilution, and using higher sensitivity ECL substrate.

We also recommend trying 1%SDS Hot lysis prepare method to get desired Western Blot results.

style

left-column

style

left-column

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"}, "ICCIF" : {"fullname" : "Immunocytochemistry/ Immunofluorescence", "shortname":"ICC/IF"}, "FlowCytIntra" : {"fullname" : "Flow Cytometry (Intracellular)", "shortname":"Flow Cyt (Intra)"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/1000", "WB-species-notes": "", "ICCIF-species-checked": "testedAndGuaranteed", "ICCIF-species-dilution-info": "1/100", "ICCIF-species-notes": "", "FlowCytIntra-species-checked": "testedAndGuaranteed", "FlowCytIntra-species-dilution-info": "1/20", "FlowCytIntra-species-notes": "" }, "Mouse": { "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/1000", "WB-species-notes": "", "ICCIF-species-checked": "guaranteed", "ICCIF-species-dilution-info": "", "ICCIF-species-notes": "", "FlowCytIntra-species-checked": "guaranteed", "FlowCytIntra-species-dilution-info": "", "FlowCytIntra-species-notes": "" }, "Rat": { "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/1000", "WB-species-notes": "", "ICCIF-species-checked": "guaranteed", "ICCIF-species-dilution-info": "", "ICCIF-species-notes": "", "FlowCytIntra-species-checked": "guaranteed", "FlowCytIntra-species-dilution-info": "", "FlowCytIntra-species-notes": "" } } }

style

left-column

Product details

Patented technology
Our RabMAb^® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb^® patents.

What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:

- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production

For more information, read more on recombinant antibodies.

style

left-column

Properties and storage information

Form

Liquid

Purification technique

Affinity purification Protein A

Storage buffer

pH: 7.2 - 7.4 Preservative: 0.01% Sodium azide Constituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA

Shipped at conditions

Blue Ice

Appropriate short-term storage duration

1-2 weeks

Appropriate short-term storage conditions

+4°C

Appropriate long-term storage conditions

-20°C

Aliquoting information

Upon delivery aliquot

Storage information

Avoid freeze / thaw cycle

style

left-column

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

ELOVL5 also known as elongation of very long chain fatty acids protein 5 is an important enzyme involved in the elongation process of fatty acids. It is part of a family that catalyzes the first and rate-limiting step of the elongation cycle adding two carbon units to the acyl chain. ELOVL5 is mainly found in tissues with high lipid metabolism including liver and brain with significant expression also noted in breast tissue. It has a molecular weight of approximately 33.5 kDa.

Biological function summary

ELOVL5 contributes to the metabolism of polyunsaturated fatty acids (PUFAs) which are important components of cell membranes and precursors to signaling molecules. It does not function alone but as part of a multi-enzyme complex that includes desaturases and reductases which enables the efficient synthesis of very long chain fatty acids (VLCFAs). These VLCFAs are critical for maintaining membrane fluidity and for cell signaling processes.

Pathways

ELOVL5 plays a significant role in the biosynthesis pathway of polyunsaturated fatty acids. It works alongside other enzymes such as desaturases to produce long-chain PUFAs from shorter precursor fatty acids. This process is important for the homeostasis of lipid signaling and membrane architecture. ELOVL5 also interacts with ELOVL6 another enzyme within the fatty acid elongation pathway indicating a coordinated interplay in fatty acid metabolism.

Mutations or deficiencies in ELOVL5 can lead to conditions affecting lipid metabolism. One such disorder is spinocerebellar ataxia 38 (SCA38) a neurodegenerative disorder characterized by issues with movement and balance. Research also suggests a link between ELOVL5 and autism spectrum disorders (ASD) though this connection requires further investigation. In these disorders ELOVL5 often interacts with other proteins involved in lipid processing such as fatty acid synthase (FASN) underlying the complex nature of these diseases.

style

left-column

style

left-column

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:

Visit the General protocols
Visit the Troubleshooting

style

left-column

Target data

Catalyzes the first and rate-limiting reaction of the four reactions that constitute the long-chain fatty acids elongation cycle. This endoplasmic reticulum-bound enzymatic process allows the addition of 2 carbons to the chain of long- and very long-chain fatty acids (VLCFAs) per cycle. Condensing enzyme that acts specifically toward polyunsaturated acyl-CoA with the higher activity toward C18 : 3(n-6) acyl-CoA. May participate in the production of monounsaturated and of polyunsaturated VLCFAs of different chain lengths that are involved in multiple biological processes as precursors of membrane lipids and lipid mediators (By similarity) (PubMed : 10970790, PubMed : 20937905). In conditions where the essential linoleic and alpha linoleic fatty acids are lacking it is also involved in the synthesis of Mead acid from oleic acid (By similarity).

See full target information ELOVL5

style

left-column

Publications (6)

Recent publications for all applications. Explore the full list and refine your search

Cancer medicine 14:e70500 PubMed39783776

2025

FXYD3 Is Frequently Expressed in Pancreatic Ductal Adenocarcinoma but Does Not Predict Survival.

Applications

Unspecified application

Species

Unspecified reactive species

Nathalie B Rasko,Christopher B Nahm,John Turchini,Rachel Teh,Helge Rasmussen,Sooin Byeon,Sumit Sahni,Jaswinder S Samra,Anthony J Gill,Anubhav Mittal

Aging 16:9437-9459 PubMed38814177

2024

Machine learning-based identification and immune characterization of ferroptosis-related molecular clusters in osteoarthritis and validation.

Applications

Unspecified application

Species

Unspecified reactive species

Xiaocheng Guo,Xinyuan Feng,Yue Yang,Wenying An,Lunhao Bai

Frontiers in physiology 12:799096 PubMed35082691

2022

Expressing the Human Cholesteryl Ester Transfer Protein Minigene Improves Diet-Induced Fatty Liver and Insulin Resistance in Female Mice.

Applications

Unspecified application

Species

Unspecified reactive species

Lin Zhu,Julia An,Sivaprakasam Chinnarasu,Thao Luu,Yasminye D Pettway,Kelly Fahey,Bridget Litts,Hye-Young H Kim,Charles R Flynn,MacRae F Linton,John M Stafford

Frontiers in genetics 12:662843 PubMed34149804

2021

Effect of the Expression of and Genes on the Metastatic Potential of Breast Cancer Cells.

Applications

Unspecified application

Species

Unspecified reactive species

Sergey Nikulin,Galina Zakharova,Andrey Poloznikov,Maria Raigorodskaya,Daniel Wicklein,Udo Schumacher,Stepan Nersisyan,Jonas Bergquist,Georgy Bakalkin,Lidiia Astakhova,Alexander Tonevitsky

Proceedings of the National Academy of Sciences of the United States of America 117:32433-32442 PubMed33288688

2020

Polyunsaturated fatty acid biosynthesis pathway determines ferroptosis sensitivity in gastric cancer.

Applications

Unspecified application

Species

Unspecified reactive species

Ji-Yoon Lee,Miso Nam,Hye Young Son,Kwangbeom Hyun,Seo Young Jang,Jong Woo Kim,Min Wook Kim,Youngae Jung,Eunji Jang,Seon-Jin Yoon,Jungeun Kim,Jihye Kim,Jinho Seo,Jeong-Ki Min,Kyoung-Jin Oh,Baek-Soo Han,Won Kon Kim,Kwang-Hee Bae,Jaewhan Song,Jaehoon Kim,Yong-Min Huh,Geum-Sook Hwang,Eun-Woo Lee,Sang Chul Lee

Lipids 55:309-327 PubMed32314395

2020

High Glucose and Liver Fatty Acid Binding Protein Gene Ablation Differentially Impact Whole Body and Liver Phenotype in High-Fat Pair-Fed Mice.

Applications

Unspecified application

Species

Unspecified reactive species

Gregory G Martin,Danilo Landrock,Avery L McIntosh,Sherrelle Milligan,Kerstin K Landrock,Ann B Kier,John Mackie,Friedhelm Schroeder

View all publications

style

left-column

style

left-column

style

right-column

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.

For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com

Anti-ELOVL5 antibody [EPR17151]

Immunocytochemistry/ Immunofluorescence - Anti-ELOVL5 antibody [EPR17151] (AB205535)

Immunocytochemistry/ Immunofluorescence - Anti-ELOVL5 antibody [EPR17151] (AB205535)

Flow Cytometry (Intracellular) - Anti-ELOVL5 antibody [EPR17151] (AB205535)

Western blot - Anti-ELOVL5 antibody [EPR17151] (AB205535)

Western blot - Anti-ELOVL5 antibody [EPR17151] (AB205535)

Western blot - Anti-ELOVL5 antibody [EPR17151] (AB205535)

Western blot - Anti-ELOVL5 antibody [EPR17151] (AB205535)

Western blot - Anti-ELOVL5 antibody [EPR17151] (AB205535)

Western blot - Anti-ELOVL5 antibody [EPR17151] (AB205535)

Related conjugates and formulations (1)

Key facts

Host species

Clonality

Clone number

Isotype

Carrier free

Reacts with

Applications

Immunogen

Specificity

Alternative Products

Primary Antibodies

Complementary Products

Assay Kits

Secondary Antibodies

Primary Antibodies

Primary Antibodies

Primary Antibodies

Reactivity data

Product details

Properties and storage information

Form

Purification technique

Storage buffer

Shipped at conditions

Appropriate short-term storage duration

Appropriate short-term storage conditions

Appropriate long-term storage conditions

Aliquoting information

Storage information

Supplementary information

Biological function summary

Pathways

Product protocols

Target data

Publications (6)

Product promise